share_log

Recursion Pharmaceuticals | DEFA14A: Others

Recursion Pharmaceuticals | DEFA14A: Others

Recursion Pharmaceuticals | DEFA14A：其他
美股SEC公告 ·  09/03 08:06

Moomoo AI 已提取核心訊息

Recursion Pharmaceuticals, Inc. (Recursion) announced the completion of its Phase 2 clinical trial for REC-994, a treatment for Cerebral Cavernous Malformation (CCM), with the primary endpoint of safety and tolerability met. The trial also showed encouraging trends in MRI-based exploratory efficacy measures. Recursion plans to present the data at a medical conference and submit for publication. Additionally, Recursion has entered into an agreement with Exscientia to combine efforts in bringing better medicines to patients more rapidly and cost-efficiently. The proposed transaction will see Exscientia shareholders receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts over the next 18 months. The transaction is subject to approval by both companies' shareholders and is expected to close by early 2025.
Recursion Pharmaceuticals, Inc. (Recursion) announced the completion of its Phase 2 clinical trial for REC-994, a treatment for Cerebral Cavernous Malformation (CCM), with the primary endpoint of safety and tolerability met. The trial also showed encouraging trends in MRI-based exploratory efficacy measures. Recursion plans to present the data at a medical conference and submit for publication. Additionally, Recursion has entered into an agreement with Exscientia to combine efforts in bringing better medicines to patients more rapidly and cost-efficiently. The proposed transaction will see Exscientia shareholders receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts over the next 18 months. The transaction is subject to approval by both companies' shareholders and is expected to close by early 2025.
Recursion Pharmaceuticals, Inc.（Recursion）宣佈完成REC-994的第二階段臨床試驗，用於治療腦凸曲瘤（CCM），主要終點安全性和耐受性得到滿足。試驗還顯示了基於MRI的探索性療效指標的鼓舞人心的趨勢。Recursion計劃在醫學會議上展示數據並提交發表。此外，Recursion與Exscientia達成協議，共同努力將更好的藥物更快更經濟地帶給患者。擬議交易將使Exscientia股東每持有1股Exscientia普通股收到0.7729股Recursion A類普通股。預計合併後的公司將擁有多樣化的臨床和近臨床項目組合，在未來18個月內將有約10個臨床數據公佈。該交易需要得到兩家公司股東的批准，並預計在2025年初閉幕。
Recursion Pharmaceuticals, Inc.（Recursion）宣佈完成REC-994的第二階段臨床試驗，用於治療腦凸曲瘤（CCM），主要終點安全性和耐受性得到滿足。試驗還顯示了基於MRI的探索性療效指標的鼓舞人心的趨勢。Recursion計劃在醫學會議上展示數據並提交發表。此外，Recursion與Exscientia達成協議，共同努力將更好的藥物更快更經濟地帶給患者。擬議交易將使Exscientia股東每持有1股Exscientia普通股收到0.7729股Recursion A類普通股。預計合併後的公司將擁有多樣化的臨床和近臨床項目組合，在未來18個月內將有約10個臨床數據公佈。該交易需要得到兩家公司股東的批准，並預計在2025年初閉幕。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間